Seatle Genetics (SGEN +1.5%) moves up today after saying it's initiated its Phase II clinical...

|By:, SA News Editor

Seatle Genetics (SGEN +1.5%) moves up today after saying it's initiated its Phase II clinical trial for Adcertris, a drug candidate to be used as a front-line therapy for patients age 60 or older with newly diagnosed Hodgkin lymphoma.